Biotechnology

PepGen

PepGen released FY2026 Q1 earnings on May 12 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -0.26 (forecast USD -0.312)

PepGen released FY2025 Q4 earnings on March 4, 2026 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -0.2666 (forecast USD -0.3742)

PepGen released FY2025 Annual Earnings on March 4, 2026 (EST), with actual revenue of USD 0 (forecast USD 0) and actual EPS of USD -2.1234 (forecast USD -2.1628)

PepGen released FY2025 Q3 earnings on November 12 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -0.5245 (forecast USD -0.565)

PepGen released FY2025 9 Months Earnings on November 12, 2025 (EST) with actual revenue of USD 0 and EPS of USD -2.1538

PepGen to showcase positive clinical data for neuromuscular therapies

Oxford Science Enterprises Acquires Ordinary Shares of PepGen Inc.

PepGen's Stock Soars on Positive Clinical Data

PepGen released FY2025 Q2 earnings on August 7, 2025 (EST), with actual revenue of USD 0 (forecast USD 0) and actual EPS of USD -0.7049 (forecast USD -0.846)

PepGen released FY2025 Semi-Annual Earnings on August 7, 2025 (EST), actual revenue USD 0, actual EPS USD -1.629

Faruqi & Faruqi Partner Encourages PepGen Investors to Contact

PepGen Inc. Sued for Making False Claims About PGN-EDO51

Gross Law Firm Notifies PepGen Shareholders of Class Action Lawsuit

PepGen Sued for Securities Fraud Related to PGN-EDO51

Rosen Firm Reminds Investors of Deadline for PepGen Stock Class Action Suit

PepGen Inc. Sued for Securities Fraud

PepGen Elects Three Directors and Confirms KPMG as Auditor

PepGen Inc. Exec VP Purchased Company Shares

HC Wainwright &amp; Co. lowers PepGen target price

OPTIMI HEALTH CORP

HCW Biologics

FLAG SHIP ACQUISITION CORPORATION COM USD0.001 (SUB/RIGHT 31/03/2026)

Micware

GCL Global

MetaVia

Arcadia Biosciences

EMMIS ACQUISITION CORP. ORD USD0.0001 (S/R 12/09/2030)

Silexion Therapeutics

PEPG

SBIO

LABU

ARKG

IBBQ

12:23 PM EDT, 05/19/2026 (MT Newswires) -- PepGen ( PEPG ) filed a registration statement Monday for the potential sale of up to $400 million of securities from time to time.The filing covers common and preferred stocks, debt securities, warrants, and units.Net proceeds will be used for general corporate purposes, the company said.Price: 1.41, Change: -0.06, Percent Change: -4.08 MT Newswires does not provide investment advice. Unauthorized reproduction is strictly prohibited.

fidelity

Invesco Biotechnology & Genome ETF

First Trust NYSE Arca Biotech Index Fd

Proshares Ultra Nasdaq Biotech

iShares Biotechnology ETF

ALPS Medical Breakthrough

SPDR S&P Biotech

VanEck Biotech ETF

Direxion S&P Biotech Bull 3X

Ark Genomic Revolution ETF

Invesco Nasdaq Biotechnology ETF

PepGen Files $400 Million Mixed Shelf

PepGen Inc.'s average stock price target has been reduced from $10.14 to $10, according to 7 analysts, with estimates ranging from $3 to $20 per share. This new target suggests a potential upside of approximately 495% based on the May 12 closing price. The consensus rating remains a 'Buy' with 6 analysts recommending 'Buy', 0 'Hold', and 1 'Sell'.

TradingView

Factset Research

PepGen Inc. Stock 12‑Month Price Target Cut to $10, Implies 495% Upside

Wedbush analyst Laura Chico has maintained a Buy rating on PepGen Inc. (PEPG) with a price target of $4.00. Chico, a 5-star analyst, has an average return of 13.2% and a success rate of 52.03%. The analyst consensus for PepGen Inc. is Moderate Buy, with a price target consensus of $10.17.

Tip Ranks

Health Care Select Sector SPDR

VG Health

Viridian Therapeutics

Ovid Therap

Maze Therapeutics

Wedbush Keeps Their Buy Rating on PepGen Inc. (PEPG)

Earnings Watch

PepGen | 8-K: FY2026 Q1 Revenue: USD 0

Shares of PepGen, Inc. (NASDAQ:PEPG) have received an average recommendation of "Moderate Buy" from six analysts. One analyst rated it as a sell, while five rated it as a buy. The average 12-month target price is $11.80. Recent price targets include a decrease from $9.00 to $5.00 by Wedbush and an increase to $7.00 by Guggenheim. PepGen's stock opened at $1.64, with a market cap of $113.35 million. Institutional investors own 58.01% of the company, which focuses on gene editing therapies for rare genetic diseases.

Market Beat

PepGen, Inc. (NASDAQ:PEPG) Given Average Recommendation of "Moderate Buy" by Brokerages

VRDN

The health care sector presents buying opportunities for undervalued stocks with low RSI values. Key stocks include PepGen Inc (PEPG), KALA BIO Inc (KALA), and Viridian Therapeutics Inc (VRDN). PepGen's stock fell 70% recently, with an RSI of 20.5. KALA BIO's stock dropped 38%, RSI at 29.3. Viridian's stock decreased 53%, RSI at 20, but analysts maintain a Buy rating. These oversold stocks may see potential breakouts as they are considered undervalued.

benzinga_article

iShares Global Healthcare

iShares US Pharma

KALA BIO

Top 3 Health Care Stocks Which Could Blast Off This Quarter

Pomerantz Law Firm is investigating claims on behalf of investors of PepGen Inc. (NASDAQ: PEPG) regarding potential securities fraud or unlawful business practices by the company and its officers. Following a partial clinical hold by the FDA on a clinical trial, PepGen's stock price fell significantly. The firm encourages affected investors to contact them for more information about joining the class action.

prnewswire

Direxion S&P Biotech Bear 3X

21:44 ETINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PepGen Inc. - PEPG

PepGen(PEPG.US)